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Refractory Hypercalcemia in Sarcoidosis: Exacerbation by thiazide 
diuretics, differentiation from primary hyperparathyroidism, and 
possible role of prolactin 
A. M. Parfitt, M D ' 
Hypercalcemia in a patient with sarcoidosis was made 
worse by a thiazide diuretic initially given to control hyper-
calciuria alone. The hypercalcemia was unusually resistant 
to corticosteroid treatment during the summer even after the 
thiazide diuretic had been discontinued. Lack of response to 
corticosteroid together with decreased tubular reabsorption 
of phosphate and increased tubular reabsorption of calcium 
suggested associated primary hyperparathyroidism, but 
PTH was undetectable by immunoassay, and nephrogenous 
cyclic AMP excretion was zero. Amenorrhea, galactorrhea 
and hyperprolactinemia were found to be due to a pituitary 
tumor which was removed. The experience with this patient 
suggests that: 1) exacerbation of hypercalcemia by thiazides 
does not discriminate between its different causes; 2) finding 
low values for plasma parathyroid homone (PTH) and 
nephrogenous cyclic AMP is the most certain way of 
excluding primary hyperparathyroidism in patients with 
hypercalcemia from other causes; 3) prolactin excess, by 
increasing the synthesis of 1,25 dihydroxycholecalciferol, 
may have intensified the calcium metabolism disorder. 
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H YPERCALCURIA leading to nephrolithiasis and hyper-
calcemia leading to nephrocalcinosis are well recognized 
complications of sarcoidosis.^ In most instances, the disor-
dered calcium metabolism is readily controlled by dietary 
calcium restriction and corticosteroids,^ but occasionally 
these measures are relatively ineffective. Such a case is the 
subject of this paper. 
Case Report 
A white woman, born in 1943, was first seen at Henry Ford EHospital 
in November, 1975 at the age of 33 for recurrent kidney stones 
associated with sarcoidosis. In 1961, at age 18, a normal pregnancy 
was followed by amenorrhea. She did not want more children and 
the cause was not estabi ished, but thyroid medication was given for 
good measure. In 1967, at age 24, a routine chest x-ray was 
abnormal; tuberculosis was suspected, but not confirmed. The 
pulmonary infiltration progressed, and three years later, in 1970, a 
biopsy o f a lymph node in the neck showed sarcoidosis. Cortico-
steroids were given for six weeks with inconclusive results. Apart 
from a skin rash on the legs, she remained well without further 
treatment for the nextthreeyears. In June, 1973, however, the first 
sign of disordered calcium metabolism abruptly appeared. This 
was a severe attack of left-sided ureteric colic which required a 
ureterolithotomy. Similar attacks of pain, but lasting only 12-24 
hours and always on the left side, recurred every few months, in 
March, 1975 a more severe attack occurred on the right side and 
required litholopaxy via cystoscopy. 
Two months later her family physician referred her to the Baylor 
College of /vledicine in Houston, Two stones were found in the left 
kidney and one in the right, all of which were removed surgically. 
The stones were composed of a mixture of calcium oxalate and 
calcium phosphate. The plasma calcium was normal at 9.2 mg/d l , 
but urinary calcium excretion was increased to 428 mg/24 hours 
on a regular diet, decreasing to 169 mgon a low calcium diet. Renal 
function was normal with a plasma creatinine of 1.0 mg/d l and a 
creatinine clearance of 101 ml/minute. The diagnosis of sar-
coidosis was confirmed by positive biopsies of a skin lesion on the 
leg and of a para-aortic lymph node. There was diffuse interstitial 
infiltration in the lungs with a combined restrictive and obstructive 
defect in ventilation. Concerning the amenorrhea, morning and 
evening plasma Cortisol, insulin tolerance test, including growth 
hormone and Cortisol response and plasma levels of luteinizing 
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hormone, triodothyronine, thyroxine, and thyroid stimulating hor-
mone were all normal. The exogenous thyroid was stopped, and 
she was discharged on a thiazide diuretic, a low calcium diet, and a 
low sodium diet, all given to lower urinary calcium excretion. 
Potassium phosphate was given as additional treatment for the 
kidney stones, but was discontinued after a few months and 
replaced by a nonphosphate containing potassium supplement. 
Although there were no further attacks of ureteric colic, urinary 
tract infections resumed and serial x-rays showed regrowth of the 
stones. 
The patient was first seen at Henry Ford Hospital six months after 
leaving Houston in November, 1975. There was no abnormality on 
physical examination apart from the abdominal scars. In particular, 
there was no enlargement of liver, spleen or lymph nodes, no 
ocular calcification, and the blood pressure was normal. The 
plasma calcium was higher (10.5 mg/d l ) and the urinary calcium 
lower (162 mg/24 hours) than previously, most likely a resultof the 
thiazide diuretic therapy. The plasma creatinine was 1.9 mg/d l and 
creatinine clearance only 50 ml/minute. The chest x-ray showed 
persistent pulmonary infiltration which had notchanged duringthe 
previous year. X-ray ofthe renal tract showed several small stones 
on the left and a single large stone on the right, which had 
progressively increased in size, although the projections were not 
precisely comparable (Figure 1). The recurrence of stones after the 
surgery in 1975 could have been due to the administration of 
supplemental phosphate to a patient with recurrent urinary tract 
infection, but the stones continued to grow even after the phos-
phate supplement had been discontinued. Despite worsen ing renal 
function and inadequate control of stone formation, no improve-
ments could be made in her treatment. 
However, in April 1976, hypercalcemia was noted forthe first time, 
the plasma calcium having risen to 11.6 mg/100 ml and the 24-
hour urinary calcium excretion to 306 mg. The dietary intake of 
calcium, determined by accurate record of food consumption fora 
week, was only 330 mg. The plasma parathyroid hormone (PTH) 
level was at the lower limit of detectability The thiazide diuretic 
wasdiscontinued, and the plasma calcium fell to 10.2 mg/100 ml. 
Thiazides were started again, and several weeks later the plasma 
calcium had risen again to 11.9 mg/100 ml. Progress over the next 
several months is shown in Figure2; all the plasma calcium values 
in this and subsequent figures are corrected for protein,^ Although 
the hypercalcemia was evidently precipitated in part by thiazides, 
the need to maintain effective suppression of urinary calcium 
excretion was critical. Consequently, the thiazide was continued 
and a trial of corticosteroids was begun, indicated also because of 
persistently abnormal ventilatory function tests. Allopurinol was 
given for hyperuricemia, a drug which may also be helpful in the 
control of calcium nephrolithiasis." The initial dose of prednisone 
was 60 mg daily then reduced to 30 mg, but the hypercalcemia 
persisted. Although hydrocortisone has occasionally been more 
effective than prednisone in the hypercalcemia of sarcoidosis,' it 
did not prove so in this case. Only when the thiazide diuretic was 
discontinued did the hypercalcemia show some response to the 
corticosteroid treatment. Note that the period of refractory hyper-
calcemia occurred during the summer months, a point which wi l l 
be taken up later. 
3-30-76 
Fig.1 
Serial plain films of renal tract over one-year period showing increase in 
size of stone and decrease in size of kidney. 
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Fig. 2 
Serial values for plasma calcium. Bendroflumethiazide worsened hyper-
calcemia and blocked the response to corticosteroid; normocalcemia was 
not restored even after the thiazide was discontinued. Note that the 
progressive rise in plasma calcium occurred during the summer. All values 
for total calcium inthis and subsequent figures are corrected for protein.' 
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Fig. 3 
Serial values for plasma calcium and inorganic phosphate while in 
hospital. There was a rapid fall in both total and ionized calcium, but mild 
hypercalcemia persisted. The combination of lasix and sodium chloride 
produced no further significant change. 
Despite the low PTH level, hypercalcemia refractory to corticoster-
oids in a patient with sarcoidosis suggested co-existing primary 
hyperparathyroidism, and in November, 1976 the patient was 
admitted to the hospital for further study. Other possible causes of 
hypercalcemia were ruled out by appropriate tests. Looking for 
further evidence of possible hyperparathyroidism, a bone biopsy 
was performed which showed an increase in the proportion of the 
trabecular surface covered by osteoclasts. Although this was 
consistent with hyperparathyroidism, other features of the bone 
biopsy were against this diagnosis. The bone mineral content ofthe 
radius measured by photon absorptiometry was normal. While 
these studies were proceeding, the dietary intake of calcium was 
further reduced to 150 mg/day, and the plasma calcium fell slowly 
to 10.1 mg/100 ml, a normal value. The ionized calcium was only 
marginally raised at 4.7 mg/100 ml (4.6 being the upper limit of 
normal). 
Rigorous dietary calcium restriction and prednisone 30 mg on 
alternate days were continued at home. Plasma calcium remained 
normal for the next six months; in May, 1977 it was 9.8 mg/100 ml 
and the serum creatinine had fallen to 1.3. The patient was 
concerned about her Cushingoid facies and a weight gain of 26 
pounds. For this reason and also because there had been no 
improvement either in the chest x-ray or in ventilatory function 
tests, prednisone was gradually withdrawn. This was quickly 
followed by a recurrence of severe hypercalcemia requiring 
hospital admission. As in the previous year this episode occurred 
during the summer months. The creatinine clearance had fallen to 
24 ml/minute, the tubular reabsorption of phosphate was de-
creased, and the tubular reabsorption of calcium was increased 
(Table 1), Although both of these findings are consistent with 
increased PTH secretion, the PTH measured by radio-immu-
noassay was undetectable and the nephrogenous cyclic adenosine 
monophosphate (Nc'AMP) excretion, a more specific test of renal 
tubular responsiveness to PTH,'^ was zero. The patient reluctantly 
agreed to the reinstitution of prednisone, which produced a rapid 
fall in plasma calcium to nearly normal (Figure 3). Two hundred 
mEq of sodium chloride combined with furosemide 80 mg daily 
was then given in the hope that increasing the urinary excretion of 
sodium would also increase urinary calcium excretion and further 
lower the plasma calcium. There was no further change in total 
calcium although there was a suggestive fall in ionized calcium. 
The possibility of a pituitary or hypothalamic cause for amenorrhea 
was reconsidered despite the previously negative investigations, 
because galactorrhea was detected for the first time. Since sarcoid 
granulomas can occur in the central nervous system, the amenor-
rhea could havebeen thefirst symptom of thedisease. Thyroid and 
adrenal function were again normal. The plasma prolactin level 
was 720 ng /ml , which was very high, and both the LH and ESH 
levels were abnormally low. Laminograms of the pituitary fossa 
indicated the presence of a tumor which was removed on February 
20,1978 bytrans-sphenoidal hypophysectomy; the plasma prolac-
tin fell to 44.6 ng /ml . The excess prolactin may have accounted for 
some ofthe unusual aspects of the disordered calcium metabolism 
as well as for amenorrhoea and galactorrhea. 
Discussion 
This patient has sarcoidosis, hypercalciuria, nephrolithiasis, 
and hypercalcemia exacerbated by thiazides but respond-
ing eventually to corticosteroids, associated with a prolactin 
secreting pituitary tumor. Three aspects ofthe case wil l be 
discussed; first, the various diagnostic procedures which 
indicated that the patient did not have hyperparathyroidism 
as well as sarcoidosis; second, the pathophysiology of the 
calcium disturbances in sarcoidosis and in thiazide diuretic 
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therapy and their possible relationship to prolactin; and 
third, the difficult problems in treating this patient. 
Differentiation between sarcoidosis with hypercalcemia 
and hyperparathyroidism 
There is no doubt that the patient had sarcoidosis, but in this 
disease there is an increased prevalence of primary hyper-
parathyroidism.'This rarely causes rapidly changing hyper-
calcemia,* but in patients w i th both diseases the 
hypercalcemia does not respond to corticosteroids, so that 
exclusion of primary hyperparathyroidism was of particular 
importance in this patienL Figure 4 shows the effect of a 
standard cortisone test, 150 mg daily for 10 days, in three 
patients, one w i th primary hyperparathyroidism who 
showed no change in plasma calcium, one with sarcoidosis 
showing a fall in plasma calcium to normal, and one with 
both diseases in whom the effect was the same as in primary 
hyperparathyroidism alone. As a general rule, when a 
patient has both primary hyperparathyroidism and some 
other disease which can cause hypercalcemia, the hyper-
calcemia is due entirely to the hyperparathyroidism. Only 
very rarely does the second disease make an independent 
contribution. 
Although the obvious way of excluding overactivity of an 
endocrine gland is to measure the relevant hormone in the 
blood, this is much more complex for PTH than for almost 
any other hormone. PTH is an 84-amino-acid polypeptide 
with biologic activity residing in the first 34 amino-acids at 
the amino terminus. Like other peptide hormones, PTH is 
measured by radio-immunoassay; in the absence of pure 
human hormone, antibodies are raised by immunizing 
animals with bovine PTH, which resembles the human 
hormone sufficiently for antibodies to crossreact. There are 
I'V HPT Alone I'y HPT + Sarcoidosis Sarcoidosis Alone 
0 2 4 6 8 10 12 14 0 2 4 6 8 10 12 14 0 2 4 6 8 10 12 14 
DAYS 
Fig. 4 
Response of plasma calcium and inorganic phosphate and 24-hour urinary 
calcium to standard cortisone test. Note the fall of plasma calcium to 
normal in sarcoidosis alone, and no significant change in primary 
hyperparathyroidism wi th or without sarcoidosis. 
at least three separate immunogenic sites along the PTH 
molecule, and different antisera may react with any com-
bination of these. The PTH molecule is broken up into 
shorter fragments both in the liver and in the kidney. The 
majorcomponent of immuno-assayable PTH in the circula-
tion is a C terminal fragment (molecularweight about 7,000 
daltons) which has a long half-life and is biologically inert. 
Cleavage at a different site may also produce a biologically 
active fragment and a shorter inactive fragment. Because of 
these complexities no one really knows what they are 
measuring by a particular radio-immunoassay. Fortunately, 
the interpretation ofa negative result is more certain. In this 
patient the PTH level was low or undetectable with four 
different assays in four different laboratories at various times. 
PTH reduces the tubular reabsorption of phosphate, and 
tests based on this action have been used in diagnosis forthe 
last 20 years. From simultaneous measurements of the 
concentrations of phosphate and creatinine in plasma and 
urine it is possible to calculate the percentage ofthe filtered 
load of phosphate which is reabsorbed, ft is physiologically 
more accurate to use the same data to calculate the mean 
threshold of phosphate excretion, which is numerically 
equal to the maximum reabsorptive capacity corrected for 
glomerular filtration rate or TmP/GFR.' This quantity is 
almost always low in hyperparathyroidism, but there are 
many other influences on phosphate excretion so that the 
test is nonspecific. Low values can occur with any form of 
hypercalcemia, as in the present case. 
PTH also increases the tubular reabsorption of calcium, 
which is best shown by relating urinary calcium excre-
tion/100 ml of creatinine clearance to the simultaneously 
measured plasma calcium. In primary hyperparathyroidism 
the urinary calcium is less than would be expected for the 
same degree of hypercalcemia produced by calcium infu-
sion, indicating increased tubular reabsorption.^"Thistest is 
nonspecific because the tubular reabsorption of calcium, as 
of phosphate, is infiueneed by many otherfactors. One in 
particular is sodium balance. Sodium depletion and con-
traction of the extracellular fluid volume lead to increased 
tubular reabsorption of sodium and also of calcium. Patients 
with severe hypercalcemia of whatever etiology are fre-
quently dehydrated because of vomiting and polyuria so 
that salt depletion and increased tubular reabsorption of 
calcium are to be expected. Forthis reason, correcfion of salt 
depletion is an important component of the treatment of 
severe hypercalcemia.^The tubular reabsorption of calcium 
in this patient when assessed in this manner was normal 
when she was first seen, and increased during the second 
episode of severe hypercalcemia, but this increase was the 
result of dehydration, notof increased PTH secretion. 
Another test based on the action of PTH on the renal tubule 
is the excret ion of cyc l ic adenosine monophosphate 
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(c'AMP). PTH, like many other peptide hormones, initiates 
its biologic effects by binding to a receptor at the cell 
membrane. This leadsto activation ofthe membrane-bound 
enzyme adenylate cyclase which catalyzes the conversion 
of ATP to c'AMP. Inthe renal tubule cell this action occurs at 
the base or antiluminal pole. Some ofthe c'AMPenters the 
cell and travels to the luminal pole where it leads to 
inhibition ofthe entry of phosphate from the tubular lumen. 
The c'AMP then passes out ofthe cell into the lumen and is 
eventually excreted in the urine. The urinary excretion of 
c'AMP is also derived from two other sources unrelated to 
the action of PTH. First, c'AMP is produced in many tissues 
by the action of catecholamines, glucagon and other hor-
mones, and the surplus c'AMP is excreted in the urine. 
Second, antidiuretic hormone also acts on the renal tubule 
by activating adenylate cyclase. By measuring the plasma 
level of c'AMP and the creatinine clearance, the filtered load 
of c'AMP can be determined and subtracted from the total 
urinary excretion to give the nephrogenous componenL In 
order to suppress ADH secretion, water diuresis is induced 
so that the nephrogenous c'AMP is then a reflection solely of 
endogenous PTH secretion, A further refinement is to ex-
press nephrogenous c'AMP excretion/100 ml creatinine 
clearance. This is a measure of the tubular response to PTH 
per unit of functioning renal tissue and can be used to assess 
parathyroid function in renal failure. Nephrogenous c'AMP 
Is somewhat less sensitive than tests based on the tubular 
reabsorption of phosphate or of calcium, in that normal 
values occur more commonly in patients with proven 
hyperparathyroidism. But ft is more precise in that elevated 
values more certainly indicate hyperparathyroidism and 
abnormally low values more certainly indicate its absence. 
In this patient the nephrogenous c'AMP was undetectable. 
Patients with hyperparathyroidism may have changes in the 
bones, usually characterized by an increase in the propor-
tion of bone surface undergoing both resorption and forma-
tion. Bone resorption is indicated microscopically by the 
presence of scalloped erosions ofthe bone surface known as 
Howship's lacunae. If these contain osteoclasts, which are 
large multinucleated cells, it is reasonable to infer that 
resorption was active at the time ofthe biopsy, but frequently 
Howship's lacunae contain other kinds of cell or no cells at 
all, indicating that resorption was probably not active. 
Normally, Howship's lacunae occupy about 5% of the total 
trabecular bone surface, but only about 10% of the How-
ship's lacunar surface is lined by osteoclasts. In the present 
case (Table I), there was a substantial increase in both the 
total resorption surface and the active or osteoclast-lined 
resorption surface, but a paradoxical decrease in the extent 
of the bone forming surface, in contrast to the increase 
usually observed in hyperparathyroidism. There was also a 
marked discrepancy between the iliac trabecular surface 
where osteoclastic resorption was increased, and the iliac 
cortex where there were no osteoclasts at all. Like the 
change in tubular reabsorption of calcium and phosphate, 
an increase in the extent of surface resorption is not specific 
for hyperparathyroidism but occurs in several other condi-
tions causing hypercalcemia, including vitamin D poison-
ing and sarcoidosis. 
TABLE I 
Diagnostic Information For and Against Concomitant 
Hyperparathyroidism (HPT) 
For HPT Against HPT 
History nephrolithiasis initial 
normocalcemia 
TmP/GFR (mg/100 ml) 2.2 (NR 2,8-4,2) 
Tubular reabsorption 
of Ca' increased 
Response to 
thiazides (TZ) plasma Ga rose 
Bone mineral content normal 
Response to 
corticosteroids 
(on TZ) no change 
Response to 
corticosteroids 
(off TZ) plasma Ca fell 
Nephrogenous c'AMP zero 
PTH undetectable 
' Based on relationship between calcium excretion (0,61 mg/100 ml 
Ccr) and plasma calcium (14,2 mg/100 ml) in comparison with 
normal values.'" 
A final point concerning the state of the bones is the 
measurement of the bone mineral content of the radius by 
photon absorptiometry. The scans are made with the Nor-
land-Cameron instrument across the forearm at two sites: a 
proximal site about one-third ofthe distance from the styloid 
process to the olecranon, where the bone is almost entirely 
cortical; and a more distal site about one-tenth of the 
distance from the olecranon, where there is a higher propor-
tion of trabecular bone. In hyperparathyroidism the values 
tend to be reduced at both sites, but there is a relatively 
greater reduction at the distal site. In our patient both values 
and the relationship between them were normal. 
The rapid response of the hypercalcemia to corticosteroids 
on the second occasion when the patient was not taking 
thiazide diuretics is very strong evidence against hyper-
parathyroidism. Typical responses to steroids are shown in 
Figure 4. Although steroid responsive hypercalcemia has 
been recorded in a few patients w i th primary hyper-
parathyroidism, they all had a more rapidly progressive form 
ofthe disease than usual, characterized by a short history, 
large tumors, and frequent presence of osteitis fibrosa. 
Slowly progressive hyperparathyroidism without overt 
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bone disease is never responsive to corticosteroids.^ 
Table II summarizes the results ofthe various diagnostic tests 
and their bearing on the presence or absence of concomitant 
hyperparathyroidism in this patienL Although exacerbation 
of hypercalcemia with thiazides is characterisfic of primary 
hyperparathyroidism, it may also occur in other cond itions. 
Each of the other test results tending to favor the d iagnosis of 
hyperparathyroidism is nonspecific and susceptible of alter-
native interpretations. On the other hand, the combination 
of undetectable PTH, zero nephrogenous cyclic AMP, and 
suppression of hypercalcemia by prednisone is conclusive 
evidence against hyperparathyroidism. 
TABLE II 
Measurements on Iliac Bone Biopsy After 
Double Tetracycline Labelling 
Normal Present 
Quantity Range Case 
Total bone volume (%TMT)* 20,2 ±4,0 12.1 
Total formation surtace (%TS)*' 12,9 ±5.8 2.2 
Osteoblast surface (%TS) 5.0 ±3.3 1.6 
Total resorption surface (%TS) 5.8 + 2,0 29.2 
Gsteoclast surface (%TS) 1.0 ±0,5 6.-3 
Gsteold seam width (um) 12.0 ±3,4 6.7 
Appositional rate(um/d) 0.75 ±0.12 0.4 
* TMT = total marrow tissue 
**TS = total surface 
The calcium disorder in sarcoidosis and its relationship to 
hyperprolactinemia and thiazide diuretic administration 
In sarcoidosis the metabolic state resembles closely that of 
vitamin D intoxication. There is increased gastrointestinal 
absorption of calcium, increased bone turnover, hyper-
calciuria, and hypercalcemia, all o fwh ich are reversed by 
the administration of corticosteroids, just as in vitamin D 
poisoning.^ Even in patients whose calcium metabolism 
appears to be normal there may be increased urinary 
hydroxyproline excretion and suppressed PTH levels, so 
that the calcium disorder probably affects all patients with 
the disease, although the intensity varies considerably from 
one patient to another."'^^ Vitamin D (or cholecalciferol), 
whether ingested as such in the diet or synthesized in the 
skin in response to irradiation by ultraviolet light, is biolog-
ically inactive. It is converted in the liver to 25-hydroxy-
cholecalciferol (25HCC), which in turn is converted in the 
kidneyeither to 1,25-dihydroxycholecalciferol (1,25DHCC) 
or to 24,25-d ihydroxycholecalc i fero l (24,25DHCC). 
25HCC is active in high dose, but 1,25DHCC is much more 
potent and is the main physiologically active metabolite. 
Patients with sarcoidosis are abnormally sensitive to vitamin 
D, in that small oral doses, such as 0.25 mg or 10,000 units 
daily, or exposure ofthe skin to ultraviolet light may induce 
hypercalcemia,^ although these procedures have no effect 
in a normal person. This abnormal sensitivity explains the 
spontaneous disappearance of hypercalcemia which may 
follow hospital admission^ as well as the seasonal variation 
in the intensity ofthe calcium disorder. In a study at Duke 
University some years ago,"al l plasmacalcium estimations 
in patients with sarcoidosis for a whole year were exam ined. 
They showed a significant increase during the summer 
months, whereas all the other values accumulated during 
the same period showed no change. In our patient, a 
seasonal fluctuation was clearly evident, and in retrospect, it 
was a mistake to withdraw corticosteroids at the beginning 
of the summer. 
Anotherconsequence ofthe increased sensitivity to sunlight 
isthe pronounced geographic variation inthe prevalence of 
the calcium disorder. In Washington DC, where summer is 
short and many patients are dark skinned, hypercalcemia is 
rare and occurs only in patients with extensive and severe 
disease.^* By contrast, in Queensland, Australia, with a 
predominantly light-skinned population exposed to tropical 
sunlight forthe entire year, hypercalciuria is almost univer-
sal and hypercalcemia occurs in 30% of patients. This is so 
even in asymptomatic persons whose only manifestation of 
the disease is enlarged hilar lymph nodes discovered by 
compulsory annual chest x-ray. 
The precise nature of the disorder of vitamin D metabolism 
in sarcoidosis remains to be determined.The plasma level 
of 25HCC is normal and rises to the sameextent as in normal 
subjects in response to vitamin D administration or to 
ultraviolet irradiation ofthe skin; thus, there is no increase in 
the conversion of vitamin D to its first metabolite in the liver. 
Plasma levels of 1,25DHCC have been measured only in a 
few patients, and values to date have been either normal or 
only marginally raised. Since the calcium hyperabsorption 
of sarcoidosis leads to suppression of PTH, and since PTH is 
one of the factors wh ich stimulates the format ion of 
1,25DHCC by the kidney, the plasma levels of this meta-
bolite should be low. A normal value, therefore, may reflect 
a failure to suppress the process of renal 1-hydroxylation. 
However, the levels in the blood are lowerthan are found in 
idiopathic hypercalciuria, in which increased intestinal 
absorption of calcium is accompanied by a normal plasma 
c a l c i u m . f t is therefore unlikely thatthe hypercalcemia of 
sarcoidosis can be attributed solely to increased production 
of 1,25DHCC. Finally, when patients with sarcoidosis are 
given 1,25DHCC they show the same increase in intestinal 
absorption and urinary excretion of calcium as normal 
persons. The increased sensitivity to vitamin D in sar-
coidosis cannot be explained within the framework of 
current knowledge of vitamin D metabolism, which sug-
gests that another, as yet unidentified, metabolite of vitamin 
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D may be produced in excessive amounts in this disease. 
In some experimental animals prolactin is a potent stimulus 
to the formation of 1,25DHCC,'' which may explain the 
increased intestinal absorption of calcium that occurs dur-
ing lactation. Enhancement by prolactin of the synthesis of 
1,25DHCC is an attractive explanation for the unusual 
refractoriness to treatment in this patient, but plasma levels 
of 1,25DHCC are not yet available. If this explanation is 
correct, her hypercalcemia should be much less of a 
problem during future summers. 
The undoubted relationship between hypercalcemia and 
thiazide diuretic administration in this patient is noteworthy. 
In normal subjects thiazides reduce the urinary excretion of 
calcium but plasma calcium corrected for protein does not 
change,^" In primary hyperparathyroidism thiazides charac-
teristically cause further elevation ofthe plasma calcium but 
may have the same effect in patients receiving high doses of 
vitamin D either for osteoporosis^' or for hypoparathyroid-
ism.^" It is therefore not surprising that thiazide-induced 
hypercalcemia should also occur in sarcoidosis; evidently, 
precipitation of hypercalcemia by thiazide diuretics does 
not necessarily indicate hyperparathyroidism. 
that the chloroquine was given coincidentally at the time of 
a spontaneous remission. If refractory hypercalcemia recurs 
in the summer despite a return of the plasma prolactin level 
to normal, chloroquine might be used in this patient. 
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Treatment of the calcium disturbance in sarcoidosis 
In patients w i th hypercalc iur ia alone urinary ca lc ium 
should be reduced if possible in orderto minimize the risk of 
nephrolithiasis. Thiazide diuretics are effective and may 
lower urinary calcium without raising plasma calcium, as in 
hypercalciuria from other causes. It is not known why 
hypercalcemia occurs in some patients but not in others. 
Corticosteroids are unsatisfactory because any beneficial 
effect due to reversal of the abnormality caused by the 
disease may be nullified by the direct hypercalciuric effect 
ofthe medication itself. Cellulose phosphate binds calcium 
and magnesium in the gut and is a useful adjunct to a low 
calcium diet,^^ but unfortunately it is not yet available in the 
United States. 
Corticosteroids are the most effective treatment for hyper-
calcemia in sarcoidosis^ and may be beneficial for other 
manifestations ofthe disease. Urinary calcium falls rapidly 
in parallel withthe plasmacalcium, in contrast to the lackof 
effect of corticosteroids on urinary calcium in patients with 
hypercalciuria alone. Nevertheless, an alternative which 
avoided the long-term harmful effects of corticosteroids 
would be valuable. Some years ago chloroquine was found 
to be effective in a few patients, possibly by minimizing in 
some way the effect of sunlight on the skin." My own 
experience with this agent is limited to a single case in 
which the administration of chloroquine was followed by a 
gradual correction of the hypercalcemia. However, since 
the disease activity was also subsiding, it is quite possible 
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